Halozyme Therapeutics (HALO) reported $1.4B in revenue for fiscal 2025, +37.6% year on year. That ranks #1564 by revenue among 2853 SEC filers and #143 in Healthcare. Net income was $317M, a net margin of 22.7%. Revenue has grown 25.8% a year on average since 2011 ($56.1M then). The fiscal 2025 balance sheet shows $2.5B in total assets, $134M in cash and $2.1B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $1.4B | +37.6% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $469M | −15.0% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $317M | −28.6% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $652M | +36.0% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $7.0M | −34.8% | FY20252025-12-31 |
| Total assetsAssets | $2.5B | +22.4% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $48.8M | −86.6% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $134M | +15.5% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $2.1B | +42.3% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $377M | $150M | Open → |
| Q2 20262026-06-30 | $481M | $230M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 21 of 161 companies compared | 22.7% | |
| Operating marginRank 12 of 160 companies compared | 33.6% | |
| R&D as share of revenueRank 71 of 102 companies compared | 5.8% | |
| Cash as share of revenueRank 88 of 160 companies compared | 9.6% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Halozyme Therapeutics, Inc.
- Ticker
- HALO
- Exchange
- Nasdaq
- SIC classification
- Biological Products, (No Diagnostic Substances) (2836)
- Fiscal year end
- 12-31
- CIK
- 0001159036
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 11, 2026Open filing →
- 10-KFeb 17, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Lifestance HealthLFST | $1.4B | $9.7M |
| Addus HomecareADUS | $1.4B | $95.9M |
| PenumbraPEN | $1.4B | $178M |
| Halozyme TherapeuticsHALO | $1.4B | $317M |
| LivanovaLIVN | $1.4B | −$243M |
| ConmedCNMD | $1.4B | $47.1M |
| Stevanato GroupSTVN | $1.3B | $158M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Halozyme Therapeutics — Key figures |url=https://companiesranked.com/en/company/halozyme-therapeutics |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Halozyme Therapeutics — Key figures. CompaniesRanked. https://companiesranked.com/en/company/halozyme-therapeuticsBibTeX
@misc{companiesranked-en-company-halozyme-therapeutics-2026,
author = {{CompaniesRanked}},
title = {{Halozyme Therapeutics — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/halozyme-therapeutics}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001159036-26-000024 · February 17, 2026
{{cite web |title=Halozyme Therapeutics — Key figures — 10-K (0001159036-26-000024) |url=https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-17}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.